Ambalal Sarabhai Enterprises Limited (BOM:500009)
India · Delayed Price · Currency is INR | Market Cap | 2.67B -1.4% |
| Revenue (ttm) | 2.02B +2.5% |
| Net Income | 178.04M +261.0% |
| EPS | 2.32 +262.5% |
| Shares Out | 76.63M |
| PE Ratio | 15.03 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 43,311 |
| Open | 32.81 |
| Previous Close | 32.16 |
| Day's Range | 31.50 - 33.34 |
| 52-Week Range | 23.12 - 40.00 |
| Beta | 0.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 21, 2026 |
About BOM:500009
Ambalal Sarabhai Enterprises Limited, together with its subsidiaries, manufactures, markets, and supplies pharmaceutical products in India and internationally. The company offers products for oncology, infertility, and uro-gynaec areas; generic and veterinary products; antifungal active ingredient products; vitamin C coated products; and analytical, test, and measuring instruments, as well as supplies finished dosage forms and active pharmaceutical ingredients. It also provides broadcast and professional video/audio, and electronic products. Am... [Read more]
Financial Performance
In fiscal year 2026, BOM:500009's revenue was 2.02 billion, an increase of 2.50% compared to the previous year's 1.97 billion. Earnings were 178.04 million, an increase of 261.05%.
Financial StatementsNews
EXCLUSIVE: Co-Diagnostics Expands South Asia Reach, Targets $13 Billion Market Opportunity
Co-Diagnostics Inc. (NASDAQ: CODX) on Friday signed an agreement for CoSara Diagnostics Pvt. Ltd , to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakista...